Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preventive Healthcare Services01:30

Preventive Healthcare Services

2.2K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Treatment Intensity on Quality of Life in Patients With Metastatic Testicular Cancer.

Andrology·2026
Same author

MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial.

European urology oncology·2026
Same author

From Evidence to Implementation: How Should We Screen for Prostate Cancer in the Modern Era?: Editorial to: Nguyen DD, Tadayon B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. 2026. In press. https://doi.org/10.1016/j.eururo.2026.04.005.

European urology·2026
Same author

[Reducing overdiagnosis-how to do I correctly assess the indication for prostate biopsy?]

Urologie (Heidelberg, Germany)·2026
Same author

Smart Screening in Prostate Cancer: What We Have Learned So Far from PROBASE.

European urology focus·2026
Same author

PRIMA: randomized prospective multicenter non-inferiority study for primary diagnosis of clinically significant PRostate cancer by PSA and MR IMAging-study protocol for a randomized diagnostic accuracy trial.

Trials·2026
Same journal

Molecular mechanisms of erectile dysfunction in type 1 and type 2 diabetic rats: a multiomics approach.

Asian journal of andrology·2026
Same journal

The long (GGN)n repeat tract in the androgen receptor gene exerts a negative effect on quantitative sperm parameters.

Asian journal of andrology·2026
Same journal

Exploring potential targets and mechanisms of male reproductive toxicity induced by the emerging PFAS GenX and F-53B via network toxicology, molecular docking, and in vivo validation.

Asian journal of andrology·2026
Same journal

Modifiable key factors and semen quality in men undergoing preconception evaluation: a cross-sectional study.

Asian journal of andrology·2026
Same journal

Somatic cell reprogramming into stem cells: approaches, mechanisms, and therapeutic applications.

Asian journal of andrology·2026
Same journal

A homozygous splicing mutation in CCDC39 caused multiple morphological abnormalities of the flagella in an infertile man with primary ciliary dyskinesia.

Asian journal of andrology·2026
See all related articles

Related Experiment Video

Updated: Feb 23, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.7K

PSA screening - for whom and when?

Peter Albers1

  • 1Department of Urology, Düsseldorf University Hospital, Heinrich-Heine-University, Moorenstr. 5, D-40225, Düsseldorf, Germany.

Asian Journal of Andrology
|September 8, 2017
PubMed
Summary
This summary is machine-generated.

Prostate cancer screening shows a 27% survival benefit, but risks overdiagnosis. Risk-adapted screening using prostate-specific antigen (PSA) levels may improve outcomes by targeting individuals most likely to benefit.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.1K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

918

Related Experiment Videos

Last Updated: Feb 23, 2026

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.7K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.1K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

918

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • Prostate cancer screening remains a topic of extensive debate.
  • The European Randomized Trial for Screening of Prostate Cancer (ERSPC) demonstrated a 27% reduction in prostate cancer-specific mortality.
  • Overdiagnosis and overtreatment are significant concerns associated with population-based screening.

Purpose of the Study:

  • To evaluate the efficacy of risk-adapted prostate-specific antigen (PSA) screening.
  • To determine if baseline PSA levels at ages 45-50 can maintain screening benefits while reducing overdiagnosis.
  • To address the ongoing question of optimal prostate cancer screening strategies.

Main Methods:

  • The PROBASE trial is a randomized, controlled study.
  • It investigates a risk-adapted screening approach based on initial PSA measurements.
  • The trial is currently underway in Germany.

Main Results:

  • The ERSPC trial showed a stable 27% relative advantage in cancer-specific survival up to 13 years.
  • Risk-adapted screening aims to mitigate the harms of overdiagnosis and overtreatment.
  • The PROBASE trial will provide data on the effectiveness of this tailored approach.

Conclusions:

  • While prostate cancer screening offers survival benefits, minimizing overdiagnosis is crucial.
  • Risk-adapted screening strategies, like those in the PROBASE trial, hold promise.
  • Further research is needed to refine prostate cancer screening protocols.